Authors

Melvin Parasram

Type

Text

Type

Thesis

Advisor

Isaac Carrico | Iwao Ojima. | Dale Drueckhammer.

Date

2011-05-01

Keywords

Chemistry -- Oncology | Beta-Lactam, Cancer, Ojima-Holton Coupling, Paclitaxel, Polyunsaturated Fatty Acids, Tumor-targeting modules

Department

Department of Chemistry

Language

en_US

Source

This work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree.

Identifier

http://hdl.handle.net/11401/71775

Publisher

The Graduate School, Stony Brook University: Stony Brook, NY.

Format

application/pdf

Abstract

Cancer is the second major cause of death in the United States and is the leading cause of death of patients below the age of 85. Traditional chemotherapeutics, such as paclitaxel (Taxol ¶©) and docetaxel (Taxotere ¶©) have had a significant impact in the field of chemotherapy because of their unique mechanism of action of inducing apoptosis by stabilizing microtubules during mitotic cell division. However, studies have indicated that these drugs are not active in multi-drug resistant (MDR) cancer cells. MDR arises from the overexpression of ATP-binding cassette proteins which enable the cancer cell to remove cytotoxic agents from the cell via ATP dependent efflux pumps, resulting in the loss of efficacy of the drug. In addition to the problem of MDR, traditional chemotherapeutics have little or no specificity, which leads to systemic toxicity, causing severe and harmful side effects. Therefore, it is important to develop next generation taxoids with increased potency and activity in MDR expressing cancers, as well as to incorporate these cytotoxic agents to tumor-targeting delivery systems to ensure selective cytotoxicity and reduce systemic toxicity. In general, these delivery systems include a tumor-targeting module (TTM) and a cytotoxic agent. Highly potent next generation taxanes, SB-T-1214, SB-T-121602, and SB-T-121302, were synthesized via Ojima-Holton coupling protocol using enantiopure Beta-lactam and modified 10-Deacetyl-Baccatin III (10-DAB). The Beta-lactam required for the Ojima-Holton coupling protocol was afforded via two synthetic routes; Staudinger [2+2] cycloaddition followed by enzymatic resolution protocol and by the chiral ester enolate-imine cyclocondensation. In addition, tumor-targeting drug conjugates were synthesized using linolenic acid (LNA) as the tumor-targeting module. LNA is an essential fatty acid which plays a crucial role in many metabolic processes. Polyunsaturated fatty acids, such as LNA, are greedily taken up by tumor cells as biochemical precursors, making them effective tumor-targeting agents. Several LNA drug conjugates were synthesized, including LNA-SB-T-1214 and LNA-SB-T-121602 as well as a tumor targeting drug conjugate that incorporates a methyl-branched disulfide linker.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.